Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancerMothaffar F. Rimawi, Rachel Schiff, Felipe C. Geyer et al.|Breast Cancer Research and Treatment|2017Cited by 95
RWD113 Impact of NGS Testing Timing on Real-World Treatment Patterns and Clinical Outcomes in Colorectal Cancer: A Retrospective Observational StudyCandice R. Gurbatri, Emilie Scherrer, Kathleen A. Burke|Value in Health|2025Cited by 0